Organization (Industry)
Kiadis Pharma (Netherlands)
ClinicalTrials.gov lists Kiadis Pharma (Netherlands) as lead sponsor of 10 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Kiadis Pharma (Netherlands): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (16)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Graft vs Host Disease | 7 |
| Myelodysplastic Syndromes | 7 |
| Hematologic Neoplasms | 6 |
| Leukemia, Myeloid, Acute | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
Showing 5 of 16 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2020 | 3 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2009 | 1 |
| 2005 | 3 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| CYCLOPHOSPHAMIDE | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 3 hit target (n=3) | 1 of 2 on time (n=2) |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation | 1 |
| Bone marrow transplantation | 1 |
| British journal of haematology | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 1 |
Showing 5 of 6 journals.
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| Sumithira Vasu | Co sponsors trial with | 1 |
| Blood and Marrow Transplant Clinical Trials Network | Co sponsors trial with | 1 |
Latest dated events (12)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-11-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-06-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2017-11-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 12 events.
Biomarker capability evidence (30)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| BCR | Trial collaborator | Named in trial inclusion criteria |
| ELN | Trial sponsor | Named in trial inclusion criteria |
| FLT3 | Trial sponsor | Named in trial inclusion criteria |
| HLA-A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 30 evidence rows.
On Scientist.com
Kiadis Pharma (Netherlands) is listed as a research supplier in the Scientist.com network.
Service areas
Kiadis provides natural products and clinical trial services.
- Website
- www.kiadis.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Kiadis on Scientist.com
For prices, more details, or to contact Kiadis, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.